Intellia Therapeutics/$NTLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Ticker
$NTLA
Sector
Primary listing
Employees
403
Headquarters
Website
NTLA Metrics
BasicAdvanced
$2.7B
-
-$4.68
2.32
-
Price and volume
Market cap
$2.7B
Beta
2.32
52-week high
$28.25
52-week low
$5.90
Average daily volume
7M
Financial strength
Current ratio
5.193
Quick ratio
4.932
Long term debt to equity
10.57
Total debt to equity
14.343
Profitability
EBITDA (TTM)
-501.874
Gross margin (TTM)
-732.63%
Net profit margin (TTM)
-908.48%
Operating margin (TTM)
-968.69%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-30.62%
Return on equity (TTM)
-56.95%
Valuation
Price to revenue (TTM)
49.662
Price to book
3.77
Price to tangible book (TTM)
3.77
Price to free cash flow (TTM)
-6.223
Free cash flow yield (TTM)
-16.07%
Free cash flow per share (TTM)
-4.114
Growth
Revenue change (TTM)
14.99%
Earnings per share change (TTM)
-14.49%
3-year revenue growth (CAGR)
5.25%
3-year earnings per share growth (CAGR)
-4.42%
What the Analysts think about NTLA
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
Bulls say / Bears say
As of June 30, 2025, Intellia held $630.5 million in cash, cash equivalents and marketable securities, providing a runway into the first half of 2027 and supporting continued development of its late-stage CRISPR programs. (Nasdaq)
Intellia’s collaboration revenue more than doubled year-over-year in Q2 2025 to $14.2 million, beating analyst estimates of $11.9 million and underscoring strong partner support, notably from its alliance with Regeneron. (Nasdaq)
Enrollment in Intellia’s global Phase 3 trials is tracking ahead of projections, with the MAGNITUDE study on course to enroll at least 650 patients by year-end and HAELO randomization expected to complete in Q3 2025, highlighting robust operational execution. (GlobeNewswire)
Intellia reported a GAAP net loss of $101.3 million (-$0.98 per share) in Q2 2025, reflecting continued unprofitability despite operational progress and highlighting the challenge of reaching profitability without product revenue. (Nasdaq)
Collaboration revenue of $14.2 million in Q2 2025 remains insufficient to cover significant R&D and G&A expenses, underlining Intellia’s reliance on external partnerships and future financing to sustain its development programs. (Nasdaq)
Despite recent gains, Intellia’s Relative Strength Rating stands at 76, below the 80 threshold common among breakout stocks, and the shares rank 267th in the Medical-Biomed/Biotech industry, indicating limited technical momentum. (Investor’s Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
NTLA Financial Performance
Revenues and expenses
NTLA Earnings Performance
Company profitability
NTLA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intellia Therapeutics stock?
Intellia Therapeutics (NTLA) has a market cap of $2.7B as of October 25, 2025.
What is the P/E ratio for Intellia Therapeutics stock?
The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of October 25, 2025.
Does Intellia Therapeutics stock pay dividends?
No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Intellia Therapeutics dividend payment date?
Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Intellia Therapeutics?
Intellia Therapeutics (NTLA) has a beta rating of 2.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.